IS6016A - Notkun á 3-hýdroxý-3-metýlglútarýl hjálparensíms A redúktasa lötum til framleiðslu á lyfi til að meðhöndla truflun í taugakerfi vegna sykursýki - Google Patents

Notkun á 3-hýdroxý-3-metýlglútarýl hjálparensíms A redúktasa lötum til framleiðslu á lyfi til að meðhöndla truflun í taugakerfi vegna sykursýki

Info

Publication number
IS6016A
IS6016A IS6016A IS6016A IS6016A IS 6016 A IS6016 A IS 6016A IS 6016 A IS6016 A IS 6016A IS 6016 A IS6016 A IS 6016A IS 6016 A IS6016 A IS 6016A
Authority
IS
Iceland
Prior art keywords
methylglutaryl
medicament
hydroxy
manufacture
treatment
Prior art date
Application number
IS6016A
Other languages
English (en)
Other versions
IS2793B (is
Inventor
Eugene Cameron Norman
Anne Cotter Mary
Original Assignee
Astrazeneca Ab
The University Court Of The University Of Aberdeen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9902591.8A external-priority patent/GB9902591D0/en
Priority claimed from GBGB9902594.2A external-priority patent/GB9902594D0/en
Application filed by Astrazeneca Ab, The University Court Of The University Of Aberdeen filed Critical Astrazeneca Ab
Publication of IS6016A publication Critical patent/IS6016A/is
Publication of IS2793B publication Critical patent/IS2793B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IS6016A 1999-02-06 2001-07-20 Notkun á 3-hýdroxý-3-metýlglútarýl hjálparensíms A afsýringarkljúfshindrum til framleiðslunnar á lyfi til að meðhöndla sykursýkitaugakvilla IS2793B (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9902591.8A GB9902591D0 (en) 1999-02-06 1999-02-06 Pharmaceutical compositions
GBGB9902594.2A GB9902594D0 (en) 1999-02-06 1999-02-06 Pharmaceutical compositions
PCT/GB2000/000280 WO2000045818A1 (en) 1999-02-06 2000-02-01 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy

Publications (2)

Publication Number Publication Date
IS6016A true IS6016A (is) 2001-07-20
IS2793B IS2793B (is) 2012-08-15

Family

ID=26315085

Family Applications (2)

Application Number Title Priority Date Filing Date
IS6016A IS2793B (is) 1999-02-06 2001-07-20 Notkun á 3-hýdroxý-3-metýlglútarýl hjálparensíms A afsýringarkljúfshindrum til framleiðslunnar á lyfi til að meðhöndla sykursýkitaugakvilla
IS8978A IS2820B (is) 1999-02-06 2011-08-23 Samsettar samsetningar sem ná yfir (E)-7-[4-(4-flúorofenýl)-6-ísóprópyl-2-[metýl(metýlsúlfónýl)-amínó]pýrimídín-5-ýl](3R,5S)-3,5-díhýdroxýhept-6-enósýru

Family Applications After (1)

Application Number Title Priority Date Filing Date
IS8978A IS2820B (is) 1999-02-06 2011-08-23 Samsettar samsetningar sem ná yfir (E)-7-[4-(4-flúorofenýl)-6-ísóprópyl-2-[metýl(metýlsúlfónýl)-amínó]pýrimídín-5-ýl](3R,5S)-3,5-díhýdroxýhept-6-enósýru

Country Status (33)

Country Link
US (4) US6894058B1 (is)
EP (2) EP1150678B1 (is)
JP (3) JP2002536332A (is)
KR (1) KR100699757B1 (is)
CN (1) CN1196488C (is)
AR (1) AR025512A1 (is)
AT (2) ATE485823T1 (is)
AU (1) AU763970B2 (is)
BR (1) BR0007996A (is)
CA (1) CA2368186C (is)
CY (2) CY1106879T1 (is)
CZ (2) CZ302881B6 (is)
DE (2) DE60035575T2 (is)
DK (2) DK1897546T3 (is)
EE (2) EE05621B1 (is)
ES (2) ES2352803T3 (is)
GB (1) GB0001662D0 (is)
HU (1) HU227642B1 (is)
IL (3) IL144730A0 (is)
IS (2) IS2793B (is)
MX (1) MXPA01007821A (is)
MY (1) MY138289A (is)
NO (1) NO330400B1 (is)
NZ (3) NZ536433A (is)
PL (1) PL198098B1 (is)
PT (2) PT1897546E (is)
RU (1) RU2239456C2 (is)
SI (2) SI1150678T1 (is)
SK (2) SK286854B6 (is)
TR (1) TR200102229T2 (is)
TW (1) TWI230067B (is)
WO (1) WO2000045818A1 (is)
ZA (1) ZA200105885B (is)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6555540B1 (en) * 1999-06-30 2003-04-29 Pfizer Inc Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
SK2692002A3 (en) 1999-08-30 2002-07-02 Aventis Pharma Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
CA2399463A1 (en) * 2000-02-10 2001-08-16 Takeda Chemical Industries, Ltd. Combination drug
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
DE10025308A1 (de) * 2000-05-23 2001-11-29 Bayer Ag Kombination von Cerivastatin mit ACE Inhibitoren und ihre Verwendung in Arzneimitteln
PE20020323A1 (es) * 2000-08-22 2002-06-13 Novartis Ag COMPOSICION FARMACEUTICA QUE COMPRENDE UN POTENCIADOR DE LA SECRESION DE INSULINA E INHIBIDORES DE HMG-Co-A-REDUCTASA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE)
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
US20060089389A1 (en) 2000-08-22 2006-04-27 Malcolm Allison Combination
CA2424060A1 (en) * 2000-10-12 2003-03-31 Nissan Chemical Industries, Ltd. Preventives and remedies for complications of diabetes
EP1326591A2 (en) * 2000-10-18 2003-07-16 Pfizer Products Inc. Combination of statins and sorbitol dehydrogenase inhibitors
CA2430309A1 (en) 2000-11-30 2002-06-06 Pfizer Products Inc. Combination of gaba agonists and aldose reductase inhibitors
US20030171407A1 (en) * 2002-03-07 2003-09-11 Upsher-Smith Laboratories, Inc. Composition for reducing blood glucose and cholesterol
AU2003209851A1 (en) * 2002-03-20 2003-09-29 The University Of Queensland Method of treatment and/or prophylaxis
AR039090A1 (es) * 2002-03-22 2005-02-09 Novartis Ag Combinacion de compuestos organicos
JP4395633B2 (ja) * 2002-08-29 2010-01-13 学校法人鈴鹿医療科学大学 非神経細胞の神経細胞への分化成熟法、該組成物と該組成物探索法
DE10302452B4 (de) * 2003-01-23 2005-02-24 Aventis Pharma Deutschland Gmbh Carbonylamino-substituierte Acyl-phenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
US7179941B2 (en) 2003-01-23 2007-02-20 Sanofi-Aventis Deutschland Gmbh Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
EP1621210B1 (en) * 2003-04-28 2013-06-19 Daiichi Sankyo Company, Limited Adiponectin production enhancer
CA2524175C (en) 2003-04-28 2016-06-14 Sankyo Company Limited Sugar intake-ability enhancer
JP2005232151A (ja) * 2003-04-28 2005-09-02 Iichiro Shimomura 糖取り込み能増強剤
ES2374399T3 (es) * 2003-06-20 2012-02-16 Nephrogenex, Inc. Piridoxamina para uso en el tratamiento de nefropatía diabética en diabetes tipo ii.
US20090082407A1 (en) * 2004-06-18 2009-03-26 Biostratum, Inc. Pyridoxamine for the Treatment of Diabetic Kidney Disease
EP1510208A1 (en) * 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
AU2003269484A1 (en) * 2003-09-11 2005-03-29 Biocon Limited Salt of atorvastatin with metformin
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
AU2003272084A1 (en) * 2003-10-07 2005-04-21 Biocon Limited SALT OF 1,2,6,7,8,8A-HEXAHYDRO-Beta,Delta,6-TRIHYDROXY-2-METHYL-8-((2S)-2-METHYL-1-OXOBUTOXY)-, (BetaR,Delta R,1S,2S,6S,8S,8AR)- 1-NAPHTHALENEHEPTANOIC ACID WITH N,N-DIMETHYL-IMIDODICARBONIMIDIC DIAMIDE
KR100715114B1 (ko) * 2005-02-19 2007-05-10 한국유나이티드제약 주식회사 당뇨병 치료를 위한 약학적 조성물
CN101632673B (zh) * 2008-07-24 2011-08-10 鲁南制药集团股份有限公司 含有氯沙坦、吡格列酮和瑞舒伐他汀的药物组合物及其新用途
ES2639019T3 (es) 2008-09-06 2017-10-25 Bionevia Pharmaceuticals Inc. Nuevo cocristal de colina de epalrestat
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
RU2014124118A (ru) 2011-11-15 2015-12-27 Др. Редди'С Лабораторис Лтд. Фармацевтические препараты, включающие аторвастатин и глимепирид
WO2015053589A1 (ko) * 2013-10-11 2015-04-16 가톨릭대학교 산학협력단 메트포민 및 스타틴의 복합제를 이용한 자가면역질환의 예방 또는 치료용 조성물
KR101579656B1 (ko) * 2013-12-12 2015-12-22 가천대학교 산학협력단 프라바스타틴과 발사르탄을 포함하는 약학 조성물
CN110747206B (zh) * 2019-11-05 2021-11-23 昆明理工大学 3-羟基-3-甲基戊二酸单酰辅酶a还原酶基因rkhmgr及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
CA2040865C (en) 1990-05-15 2002-07-23 James L. Bergey Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
US5298497A (en) 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
US5140012A (en) 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin
US5622985A (en) 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
US5190970A (en) 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5130333A (en) * 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
CA2052014A1 (en) * 1990-10-19 1992-04-20 Henry Y. Pan Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
ES2135472T3 (es) 1992-04-13 1999-11-01 Zeneca Ltd Antagonistas de angiotensina ii contra trastornos asociados con la velocidad de conduccion neuronal deteriorada, especialmente la neuropatia diabetica.
GB9208116D0 (en) * 1992-04-13 1992-05-27 Ici Plc Therapeutic agents
WO1995013063A1 (en) 1993-11-09 1995-05-18 Merck & Co., Inc. HMG-CoA REDUCTASE INHIBITORS IN THE NORMALIZATION OF VASCULAR ENDOTHELIAL DYSFUNCTION
CA2186606A1 (en) 1994-03-29 1995-10-05 Edward B. Nelson Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
RU2188013C2 (ru) 1996-04-05 2002-08-27 Такеда Кемикал Индастриз, Лтд. Комбинация, содержащая соединение, имеющее ангиотензин ii антагонистическую активность
GB9714274D0 (en) * 1997-07-08 1997-09-10 Zeneca Ltd Pharmaceutical composition
GT199800126A (es) 1997-08-29 2000-01-29 Terapia de combinacion.
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6262076B1 (en) * 2000-01-28 2001-07-17 Ajinomoto Co., Inc. Pharmaceutical composition for use in the treatment of diabetic neuropathy
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment

Also Published As

Publication number Publication date
CA2368186C (en) 2008-06-03
CZ302881B6 (cs) 2012-01-04
BR0007996A (pt) 2001-10-30
IL208330A0 (en) 2010-12-30
IL144730A0 (en) 2002-06-30
WO2000045818A1 (en) 2000-08-10
EE200100405A (et) 2002-10-15
ATE367162T1 (de) 2007-08-15
PL198098B1 (pl) 2008-05-30
ES2352803T3 (es) 2011-02-23
NO20013812D0 (no) 2001-08-03
US20090186908A1 (en) 2009-07-23
MY138289A (en) 2009-05-29
CN1338937A (zh) 2002-03-06
ES2286995T3 (es) 2007-12-16
US6894058B1 (en) 2005-05-17
CN1196488C (zh) 2005-04-13
KR100699757B1 (ko) 2007-03-27
KR20010089635A (ko) 2001-10-06
CY1110992T1 (el) 2015-06-11
ZA200105885B (en) 2002-10-17
CZ20012806A3 (cs) 2002-02-13
SK11102001A3 (sk) 2002-05-09
IS8978A (is) 2011-08-23
GB0001662D0 (en) 2000-03-15
MXPA01007821A (es) 2004-08-19
JP2002536332A (ja) 2002-10-29
NO330400B1 (no) 2011-04-04
EE201200015A (et) 2012-10-15
US20120041010A1 (en) 2012-02-16
JP2012051898A (ja) 2012-03-15
AU2304700A (en) 2000-08-25
US20050209128A1 (en) 2005-09-22
IL144730A (en) 2010-12-30
AR025512A1 (es) 2002-12-04
SK286854B6 (sk) 2009-06-05
DE60045168D1 (de) 2010-12-09
EP1897546B1 (en) 2010-10-27
NZ513061A (en) 2003-06-30
TR200102229T2 (tr) 2001-12-21
CY1106879T1 (el) 2012-05-23
IS2793B (is) 2012-08-15
PL350312A1 (en) 2002-12-02
NZ525419A (en) 2004-12-24
DE60035575D1 (de) 2007-08-30
CA2368186A1 (en) 2000-08-10
SI1150678T1 (sl) 2008-02-29
HK1118209A1 (en) 2009-02-06
DK1150678T3 (da) 2007-10-08
EE05621B1 (et) 2013-02-15
HUP0105138A3 (en) 2002-11-28
EP1897546A1 (en) 2008-03-12
NZ536433A (en) 2006-08-31
NO20013812L (no) 2001-10-02
IS2820B (is) 2012-12-15
HUP0105138A2 (hu) 2002-04-29
HU227642B1 (en) 2011-10-28
CZ302893B6 (cs) 2012-01-11
SK287792B6 (sk) 2011-10-04
HK1041223A1 (en) 2002-07-05
EE05556B1 (et) 2012-08-15
DE60035575T2 (de) 2008-04-03
EP1150678A1 (en) 2001-11-07
TWI230067B (en) 2005-04-01
PT1150678E (pt) 2007-09-14
AU763970B2 (en) 2003-08-07
PT1897546E (pt) 2010-12-15
RU2239456C2 (ru) 2004-11-10
EP1150678B1 (en) 2007-07-18
SI1897546T1 (sl) 2011-02-28
DK1897546T3 (da) 2011-01-17
JP2014065718A (ja) 2014-04-17
ATE485823T1 (de) 2010-11-15

Similar Documents

Publication Publication Date Title
IS6016A (is) Notkun á 3-hýdroxý-3-metýlglútarýl hjálparensíms A redúktasa lötum til framleiðslu á lyfi til að meðhöndla truflun í taugakerfi vegna sykursýki
HU0003863D0 (en) Alpha-sulfonylamino hidroxamic acid inhibitors of matrix metalloproteinases for the treatment of peripheral or central nervous system disorders
IS5085A (is) Nefholssamsetningar til meðhöndlunar á kynferðistruflunum
IS2907B (is) Bensó[d]asepínafleiður til að meðhöndla taugakvilla
AU9287401A (en) Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
IS6003A (is) Mónóamín endurupptökulatar til meðhöndlunar á truflunum í miðtaugakerfi
IS6377A (is) Pýrrólidínasetamíð afleiður einar sér eða í samsetningu til meðhöndlunar á truflunum í miðtaugakerfi
NO20022087D0 (no) Fremgangsmåte for behandling av diabetes
NO20004688L (no) Terapi ved østrogenassosierte lidelser
AU6910600A (en) Methods for the treatment of mental disorders
PT1154777E (pt) Medicamento para o tratamento de hipertensao arterial
WO2001098279A3 (en) Bis-arylsulfones
IS6137A (is) Meðhöndlun á hugsýkistruflunum
ID27214A (id) Triazolopiridina untuk pengobatan gangguan trombosis
IT1306165B1 (it) Impiego di inibitori della sostanza p per il trattamento degliadenocarcinomi.
AU2002227895A1 (en) Sulphonamides for the treatment of central nervous system diseases
AU2432001A (en) Treatment of mental conditions including depression
AU2003289652A1 (en) The use of compound helicid for manufacturing medicine to treat depresion and/or disorders caused by depresion
ITRM990707A0 (it) Composizione per la prevenzione e/o il trattamento di disturbi dovutiad un alterato metabolismo dei lipidi, che comprende propionil l-carni
IS6098A (is) Ósantant til meðhöndlunar á skaptruflunum
AU3899100A (en) Treatment of hyperactivity disorders
AU2002354698A1 (en) Use of xaa-pro peptidases for the treatment of substance p-related disorders
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
AU1522101A (en) Heparanase inhibitors for the treatment of heart failure
IS5481A (is) Samsett meðferð til meðhöndlunar á alnæmi